Dare Bioscience (DARE) Other Non Operating Income (2013 - 2026)
Dare Bioscience's (DARE) quarterly Other Non Operating Income came in at -$276570.0 in Q4 2025, down 114.99% YoY from $1.8 million in Q4 2024, and down 352.85% on a QoQ basis from $109382.0 in Q3 2025.
Dare Bioscience (DARE) Other Non Operating Income (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 12 years of Other Non Operating Income data on file, last reported at -$276570.0 in Q4 2025.
- Quarterly Other Non Operating Income fell 114.99% year-over-year to -$276570.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$153060.0 (down 115.59% YoY) and the FY2025 annual result came in at -$153060.0, down 115.59% from the prior year.
- Other Non Operating Income retreated to -$276570.0 in Q4 2025, from $109382.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.8 million in Q4 2024 to a low of -$732883.0 in Q1 2024.
- A 5-year average of $107737.5 and a median of $29676.0 in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income surged 59200.0% — and 2024, when it slumped 315.46%.
- Tracing DARE's Other Non Operating Income over 5 years: stood at $834.0 in 2021, then jumped by 34353.72% to $287344.0 in 2022, then plunged by 60.36% to $113898.0 in 2023, then soared by 1519.68% to $1.8 million in 2024, then sank by 114.99% to -$276570.0 in 2025.
- The last three Other Non Operating Income figures came in at -$276570.0 (Q4 2025), $109382.0 (Q3 2025), and -$188683.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,793.00 |
| Dec 31, 2025 | -276,570.00 |
| Sep 30, 2025 | 109,382.00 |
| Jun 30, 2025 | -188,683.00 |
| Mar 31, 2025 | 202,811.00 |
| Dec 31, 2024 | 1.84 Mn |
| Sep 30, 2024 | -21,152.00 |
| Jun 30, 2024 | -109,254.00 |
| Mar 31, 2024 | -732,883.00 |
| Dec 31, 2023 | 113,898.00 |
| Sep 30, 2023 | 97,319.00 |
| Jun 30, 2023 | 227,124.00 |
| Mar 31, 2023 | 340,148.00 |
| Dec 31, 2022 | 287,344.00 |
| Sep 30, 2022 | 118,950.00 |
| Jun 30, 2022 | 29,676.00 |
| Mar 31, 2022 | 1,779.00 |
| Dec 31, 2021 | 834.00 |
| Sep 30, 2021 | 1,508.00 |
| Mar 31, 2021 | 3.00 |